Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apolipoproteins | 13 | 2019 | 201 | 2.350 |
Why?
|
| Lipoproteins, HDL | 12 | 2016 | 257 | 2.270 |
Why?
|
| African Americans | 20 | 2019 | 1435 | 1.640 |
Why?
|
| Kidney Diseases | 6 | 2019 | 249 | 1.280 |
Why?
|
| Diabetic Nephropathies | 3 | 2016 | 228 | 1.060 |
Why?
|
| Polymorphism, Single Nucleotide | 12 | 2018 | 1078 | 0.960 |
Why?
|
| Kidney | 3 | 2019 | 528 | 0.890 |
Why?
|
| Kidney Failure, Chronic | 7 | 2019 | 548 | 0.890 |
Why?
|
| Acetyl-CoA Carboxylase | 3 | 2013 | 23 | 0.820 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2018 | 849 | 0.780 |
Why?
|
| Kidney Transplantation | 4 | 2019 | 515 | 0.680 |
Why?
|
| Diabetes Mellitus, Type 2 | 8 | 2017 | 1523 | 0.560 |
Why?
|
| Sepsis | 1 | 2019 | 167 | 0.550 |
Why?
|
| Renal Dialysis | 3 | 2019 | 282 | 0.500 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.500 |
Why?
|
| RNA, Messenger | 3 | 2014 | 545 | 0.480 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2019 | 302 | 0.430 |
Why?
|
| Mesangial Cells | 1 | 2014 | 10 | 0.430 |
Why?
|
| Genotype | 7 | 2019 | 743 | 0.420 |
Why?
|
| Kidney Glomerulus | 1 | 2014 | 30 | 0.420 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2014 | 40 | 0.420 |
Why?
|
| Risk Factors | 10 | 2019 | 4136 | 0.390 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 85 | 0.380 |
Why?
|
| Adipose Tissue | 5 | 2016 | 366 | 0.360 |
Why?
|
| Humans | 30 | 2019 | 34497 | 0.360 |
Why?
|
| Metabolism | 1 | 2011 | 7 | 0.350 |
Why?
|
| Obesity | 3 | 2016 | 1246 | 0.350 |
Why?
|
| Graft Survival | 3 | 2019 | 315 | 0.340 |
Why?
|
| Tissue Donors | 3 | 2019 | 208 | 0.340 |
Why?
|
| Genome-Wide Association Study | 6 | 2018 | 555 | 0.340 |
Why?
|
| Middle Aged | 18 | 2018 | 12707 | 0.340 |
Why?
|
| Fatty Acids | 1 | 2010 | 108 | 0.320 |
Why?
|
| Body Mass Index | 1 | 2013 | 954 | 0.300 |
Why?
|
| Genetic Association Studies | 4 | 2015 | 149 | 0.260 |
Why?
|
| Lupus Nephritis | 2 | 2018 | 30 | 0.250 |
Why?
|
| Gene Expression Regulation | 4 | 2016 | 526 | 0.250 |
Why?
|
| Glomerulonephritis | 2 | 2018 | 19 | 0.240 |
Why?
|
| Male | 17 | 2018 | 20713 | 0.240 |
Why?
|
| Tumor Virus Infections | 2 | 2018 | 22 | 0.240 |
Why?
|
| Polyomavirus Infections | 2 | 2018 | 21 | 0.240 |
Why?
|
| Hepatocytes | 2 | 2017 | 84 | 0.230 |
Why?
|
| Female | 16 | 2018 | 21499 | 0.230 |
Why?
|
| European Continental Ancestry Group | 5 | 2017 | 1176 | 0.220 |
Why?
|
| Adult | 12 | 2016 | 10019 | 0.220 |
Why?
|
| Genetic Variation | 2 | 2015 | 254 | 0.210 |
Why?
|
| Mice | 4 | 2019 | 2691 | 0.200 |
Why?
|
| Cells, Cultured | 2 | 2016 | 887 | 0.200 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 367 | 0.190 |
Why?
|
| Insulin Resistance | 3 | 2017 | 488 | 0.190 |
Why?
|
| Risk | 3 | 2019 | 325 | 0.190 |
Why?
|
| Liver | 2 | 2017 | 510 | 0.180 |
Why?
|
| Disease Progression | 3 | 2019 | 633 | 0.180 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 155 | 0.180 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 573 | 0.150 |
Why?
|
| Alleles | 1 | 2019 | 257 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 58 | 0.140 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 270 | 0.140 |
Why?
|
| Quantitative Trait Loci | 2 | 2016 | 142 | 0.140 |
Why?
|
| JC Virus | 2 | 2018 | 20 | 0.130 |
Why?
|
| Fibroblast Growth Factors | 1 | 2017 | 36 | 0.130 |
Why?
|
| Animals | 4 | 2019 | 8544 | 0.130 |
Why?
|
| DNA | 1 | 2018 | 235 | 0.130 |
Why?
|
| Lipogenesis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Continental Population Groups | 1 | 2018 | 245 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 5 | 2017 | 315 | 0.130 |
Why?
|
| Aged | 6 | 2016 | 11002 | 0.130 |
Why?
|
| Mutation | 1 | 2018 | 529 | 0.120 |
Why?
|
| Muscles | 1 | 2016 | 69 | 0.120 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3618 | 0.120 |
Why?
|
| Cholesterol | 1 | 2017 | 273 | 0.120 |
Why?
|
| Mice, Knockout | 2 | 2017 | 484 | 0.120 |
Why?
|
| Caveolin 1 | 1 | 2015 | 15 | 0.110 |
Why?
|
| Molecular Motor Proteins | 1 | 2015 | 60 | 0.110 |
Why?
|
| Myosin Heavy Chains | 1 | 2015 | 89 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2016 | 509 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 66 | 0.110 |
Why?
|
| Proteomics | 1 | 2015 | 106 | 0.110 |
Why?
|
| Podocytes | 1 | 2014 | 20 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 98 | 0.110 |
Why?
|
| Autoantigens | 1 | 2013 | 16 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 164 | 0.100 |
Why?
|
| Epithelial Cells | 1 | 2014 | 148 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 86 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2017 | 765 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 268 | 0.100 |
Why?
|
| Cell Line | 1 | 2014 | 476 | 0.100 |
Why?
|
| Nephrectomy | 1 | 2014 | 127 | 0.100 |
Why?
|
| Demography | 1 | 2013 | 112 | 0.100 |
Why?
|
| Indians, North American | 1 | 2013 | 110 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2013 | 268 | 0.090 |
Why?
|
| Triglycerides | 1 | 2013 | 249 | 0.090 |
Why?
|
| Adolescent | 3 | 2016 | 3801 | 0.090 |
Why?
|
| Environmental Exposure | 1 | 2012 | 91 | 0.090 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2011 | 2 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 79 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2012 | 153 | 0.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 1209 | 0.080 |
Why?
|
| Kidney Function Tests | 3 | 2017 | 107 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2011 | 149 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 801 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2011 | 118 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2018 | 924 | 0.080 |
Why?
|
| Gene Expression | 1 | 2011 | 362 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2011 | 242 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 803 | 0.080 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 282 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2011 | 265 | 0.080 |
Why?
|
| Phenotype | 3 | 2016 | 656 | 0.070 |
Why?
|
| Young Adult | 4 | 2016 | 2827 | 0.070 |
Why?
|
| United States | 4 | 2017 | 4267 | 0.060 |
Why?
|
| Creatinine | 2 | 2017 | 206 | 0.060 |
Why?
|
| Albuminuria | 2 | 2017 | 181 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2016 | 304 | 0.050 |
Why?
|
| Prevalence | 2 | 2017 | 1034 | 0.050 |
Why?
|
| Time Factors | 2 | 2016 | 2352 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2366 | 0.040 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2018 | 5 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 71 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 103 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2017 | 68 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2017 | 180 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 141 | 0.030 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2015 | 10 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 193 | 0.030 |
Why?
|
| Nephritis | 1 | 2015 | 15 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 29 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2015 | 38 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 142 | 0.030 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 26 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2015 | 45 | 0.030 |
Why?
|
| Tissue and Organ Procurement | 1 | 2016 | 99 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 56 | 0.030 |
Why?
|
| Donor Selection | 1 | 2015 | 36 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 319 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 221 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 389 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 480 | 0.030 |
Why?
|
| Registries | 1 | 2016 | 328 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 703 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 273 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 565 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 44 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2013 | 222 | 0.020 |
Why?
|
| Cystatin C | 1 | 2013 | 33 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1910 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 77 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 57 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 772 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1262 | 0.020 |
Why?
|
| Cognition | 1 | 2016 | 576 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 464 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2016 | 901 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2011 | 50 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1607 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2017 | 837 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 204 | 0.020 |
Why?
|
| Family | 1 | 2011 | 123 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 1946 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 52 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 143 | 0.020 |
Why?
|
| Genome, Human | 1 | 2011 | 136 | 0.020 |
Why?
|
| Genomics | 1 | 2011 | 94 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 202 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1387 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 1031 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 1024 | 0.020 |
Why?
|
| North Carolina | 1 | 2013 | 1612 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1603 | 0.020 |
Why?
|